ArticleDrug design, development and therapy2015
Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model.
Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Pooled it
- Potentiality of ghrelin as antioxidant and protective agent.Redox report : communications in free radical research · 2021Pooled it
- Role of Growth Hormone (GH) and Other Somatotropic Axis Elements in Retinal Neuroprotection.Current issues in molecular biology · 2026Review
- Ghrelin alleviates high glucose-induced retinal microvascular endothelial cell injury by activating Nrf2/HO-1 pathway to inhibit ferroptosis.International journal of ophthalmology · 2025Article
- Protective effect of ghrelin in oxidative stress-induced age-related macular degeneration in vitro and in vivo.Molecular medicine (Cambridge, Mass.) · 2024Article
- Changes in Circulating Acylated Ghrelin and Neutrophil Elastase in Diabetic Retinopathy.Medicina (Kaunas, Lithuania) · 2024Article
- Glaucoma and microglia-induced neuroinflammation.Frontiers in ophthalmology · 2023Review
- The ghrelin-GHSR-1a pathway inhibits high glucose-induced retinal angiogenesis in vitro by alleviating endoplasmic reticulum stress.Eye and vision (London, England) · 2022Article
- Ghrelin Ameliorates Diabetic Retinal Injury: Potential Therapeutic Avenues for Diabetic Retinopathy.Oxidative medicine and cellular longevity · 2021Article
- Glaucoma and Antioxidants: Review and Update.Antioxidants (Basel, Switzerland) · 2020Review
- Article
- Neuroprotective Peptides in Retinal Disease.Journal of clinical medicine · 2019Review
- Development and characterization of a new rat ocular hypertension model induced by intracameral injection of conjunctival fibroblasts.Scientific reports · 2019Article
- Strategies to Reduce Oxidative Stress in Glaucoma Patients.Current neuropharmacology · 2018Review
- Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function inFrontiers in molecular neuroscience · 2017Article
- Risperidone-Induced Renal Damage and Metabolic Side Effects: The Protective Effect of Resveratrol.Oxidative medicine and cellular longevity · 2017Article
- NOVELTIES IN MEDICAL TREATMENT OF GLAUCOMA.Romanian journal of ophthalmologyReview
- Targets of Neuroprotection in Glaucoma.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and TherapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Damage to retinal ganglion cells due to elevation of intraocular pressure (IOP) is responsible for vision loss in glaucoma. Given that loss of these cells is irreversible, neuroprotection is crucial in the treatment of glaucoma. In this study, we investigated the possible antioxidant and neuroprotective effects of ghrelin on the retina in an experimental glaucoma model. Twenty-one Sprague-Dawley rats were randomly assigned to three groups comprising seven rats each. The rats in the control group were not operated on and did not receive any treatment. In all rats in the other groups, IOP was increased by cauterization of the limbal veins. After creation of the IOP increase, saline 1 mL/kg or ghrelin 40 μg/kg was administered intraperitoneally every day for 14 days in the vehicle control group and ghrelin groups, respectively. On day 14 of the study, the eyes were enucleated. Levels of malondialdehyde (MDA), nitric oxide (NO), and nitric oxide synthase-2 (NOS2) in anterior chamber fluid were measured. The retinas were subjected to immunohistochemistry staining for glial fibrillary acidic protein (GFAP), S-100, and vimentin expression. Mean levels of MDA, NO, and NOS2 in the aqueous humor were higher in the vehicle control group than in the control group (P<0.05). Mean levels of MDA, NO, and NOS2 in the ghrelin group did not show a significant increase compared with levels in the control group (P>0.05). Retinal TUNEL and immunohistochemistry staining in the vehicle control group showed an increase in apoptosis and expression of GFAP, S-100, and vimentin compared with the control group (P<0.05). In the ghrelin group, apoptosis and expression of GFAP, S-100, and vimentin was significantly lower than in the vehicle control group (P<0.05). This study suggests that ghrelin has antioxidant and neuroprotective effects on the retina in an experimental glaucoma model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.